Management of cardiac adverse events occurring with sunitinib treatment

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1627-1629

  Schmidinger, Manuela ^a   Bojic, Andja ^a   Vogl, Ursula M ^a   Lamm, Wolfgang ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular; Renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADULT; ARTICLE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR SYMPTOM; CASE REPORT; CLINICAL FEATURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; DIURETICS; DRUG THERAPY, COMBINATION; HEART; HUMANS; INDOLES; MALE; MIDDLE AGED; PYRROLES;

EID: 67650081102     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Motzer RJ, Hutson TE, Tomczak P et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007. (Pubitemid 46089672)
2. Ljungberg B, Hanbury D, Kuczyk M et al: Guidelines on Renal Cell Carcinoma. Update March 2007. http://wwwuroweborg/fileadmin/user-upload/ Guidelines/08-Renal-Cell-Carcinoma-2007pdf2007.
3. Figlin RA, Hutson TE, Tomczak P et al: Overall survival with sunitinib versus (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 (May 20 suppl; abstr 5024; oral presentation), 2008.
4. Schmidinger M, Zielinski CC, Vogl UM et al: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26: 5204-5212, 2008.
5. Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2002. (Pubitemid 34032623)
6. Bevacizumab (Avastin®) Summary of Product Characteristics. Roche Products Limited, August 2008.
7. Zhu X, Wu S, Dahut WL and Parikh CR: Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193, 2007. (Pubitemid 46178407)
8. Sorafenib (Nexavar®) Summary of Product Characteristics. Bayer plc, April 2008.
9. Wu S, Chen JJ, Kudelka A, Lu J and Zhu X: Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9: 117-123, 2008.